Candel Therapeutics (CADL) Current Assets (2020 - 2025)

Candel Therapeutics (CADL) has 6 years of Current Assets data on file, last reported at $121.4 million in Q4 2025.

• For the quarter ending Q4 2025, Current Assets rose 16.94% year-over-year to $121.4 million; the trailing twelve-month figure through Dec 2025 stood at $121.4 million (up 16.94% YoY), and the FY2025 full-year result was $121.4 million, up 16.94% from the prior year.
• Current Assets climbed to $121.4 million in Q4 2025, from $90.1 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $121.4 million in Q4 2025 to a low of $18.1 million in Q3 2024.
• A 5-year average of $69.0 million and a median of $79.1 million in 2022 frame the typical range for Current Assets.
• Across the five-year window, Current Assets sank 59.9% in 2024 and soared 398.39% in 2025, its largest moves.
• Tracing CADL's Current Assets over 5 years: stood at $84.9 million in 2021, then fell by 15.3% to $71.9 million in 2022, then tumbled by 48.85% to $36.8 million in 2023, then surged by 182.1% to $103.8 million in 2024, then rose by 16.94% to $121.4 million in 2025.
• Business Quant data shows CADL's Current Assets at $121.4 million in Q4 2025, $90.1 million in Q3 2025, and $103.6 million in Q2 2025.